Form 8-K VERTEX PHARMACEUTICALS For: Feb 05
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Vertex (VRTX) PT Raised to $220 at Cowen
February 6, 2019 7:52 AM ESTCowen analyst Phil Nadeau raised the price target on Vertex (NASDAQ: VRTX) to $220.00 (from $210.00) while maintaining a Outperform rating.
The analyst commented, "VRTX reported Q4 CF franchise revenue of $868.2MM vs consensus of $818.8MM, non-GAAP EPS of $1.30 vs. consensus of $1.08. 2019 revenue guidance... More
Maxim Group Downgrades Vertex (VRTX) to Hold
February 6, 2019 7:45 AM ESTMaxim Group analyst Jason McCarthy downgraded Vertex (NASDAQ: VRTX) from Buy to Hold.
The analyst highlighted:
Vertex reported 4Q18 with cystic fibrosis (CF) revenue of $868M, representing sequential growth of 11% and beating consensus of $816M; the results include Kalydeco revenue of $259M vs. $250.5M... More